BLA 103471 · Bayer Healthcare Pharms
Betaseron
Interferon Beta-1b · Subcutaneous
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Jul 23, 1993
Approved uses
5
Original approval plus efficacy supplements
Registered trials
54
12 Phase 3, 0 recruiting
FAERS reports
19,082
10,670 serious, 1,337 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 3, 2026.
BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BETASERON is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: The mechanism of action of BETASERON (interferon beta-1b) in patients with multiple sclerosis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 26, 2017 Supplement 5189 · Efficacy LetterReview
- Sep 25, 2015 Supplement 5186 · Efficacy LabelReviewLetter
- Oct 20, 2006 Supplement 5081 · Efficacy
- Mar 14, 2003 Supplement 1039 · Efficacy · priority review OrphanLetterLabelReview
- Jul 23, 1993 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- BETASERON · INTERFERON BETA-1B 0.3 MG · VIAL, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Interferon Beta-1b" as an intervention, any sponsor and status, largest first.
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00099502 · 2,244 participants · Start Nov 2003
Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) and 1 more · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 199 sites in all
- BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New DosePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00459667 · 1,420 participants · Start May 2007 · Primary completion Mar 2008
Drug: Interferon beta-1b (Betaseron, BAY86-5046); Interferon beta-1b (Betaseron, BAY86-5046) and 1 more · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 184 sites in all
- A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01216072 · 1,053 participants · Start Aug 2010 · Primary completion Aug 2012
Drug: Fingolimod; Standard MS DMTs · For: Relapsing Forms of Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 149 sites in all
- Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01623596 · 881 participants · Start Jun 8, 2012 · Primary completion Jul 13, 2015
Drug: Fingolimod; Disease Modifying therapy · For: Relapsing Remitting Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Sun City, Arizona · 123 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Pivotal-lookingStatus unknown
Nuron Biotech Inc.Industry
NCT01464905 · 500 participants (planned) · Start Oct 2011 · Primary completion Dec 2013
Drug: NU100; Placebo and 1 more · For: Relapsing Remitting Multiple Sclerosis
Sites: Minsk, Belarus; Sofia, Bulgaria; Zagreb, Croatia · 12 sites in all
- BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00185211 · 468 participants · Start Aug 2002 · Primary completion May 2008
Drug: Interferon beta-1b (Betaseron, BAY86-5046); Interferon beta-1b (Betaseron, BAY86-5046) · For: Multiple Sclerosis
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 94 sites in all
- Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for AggravationPivotal-lookingCompleted
University Hospital, BordeauxAcademic, hospital or other
NCT04356495 · 412 participants · Start Jul 29, 2020 · Primary completion Oct 8, 2021
Drug: Telmisartan; Ciclesonide and 1 more · For: Corona Virus Infection; Sars-CoV2
Sites: Bordeaux, France; Dijon, France; Montpellier, France · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- influenza like illness1,404
- multiple sclerosis relapse1,346
- injection site pain1,198
- fatigue1,197
- multiple sclerosis1,166
- injection site erythema978
- drug ineffective970
- pain855
- headache844
- injection site reaction842
- fall819
- depression815
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 405 |
| 2005 | 535 |
| 2006 | 803 |
| 2007 | 1,200 |
| 2008 | 368 |
| 2009 | 502 |
| 2010 | 747 |
| 2011 | 1,162 |
| 2012 | 1,785 |
| 2013 | 1,656 |
| 2014 | 1,564 |
| 2015 | 1,381 |
| 2016 | 1,393 |
| 2017 | 1,291 |
| 2018 | 1,158 |
| 2019 | 986 |
| 2020 | 583 |
| 2021 | 400 |
| 2022 | 352 |
| 2023 | 322 |
| 2024 | 197 |
| 2025 | 176 |
| 2026 | 115 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Betaseron (Interferon Beta-1b)
2024 spending
$92.2M
Beneficiaries
1,042
9,136 claims
Per beneficiary
$88,521
$689.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $163,581,521 |
| 2021 | $130,156,657 |
| 2022 | $118,527,291 |
| 2023 | $103,287,436 |
| 2024 | $92,238,675 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Betaseron: the new MS treatment.
Kelley CL, Smeltzer SC · J Neurosci Nurs 1994 · Clinical Trial, Multicenter Study
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- The interferon-beta 1b clinical trial and its implications for other trials.
Paty DW · Ann Neurol 1994 · Clinical Trial, Controlled Clinical Trial
- Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.
Arabi YM, Asiri AY, Assiri AM, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Fluvoxamine treatment of major depression associated with multiple sclerosis.
Benedetti F, Campori E, Colombo C, et al. · J Neuropsychiatry Clin Neurosci 2004 · Clinical Trial, Comparative Study
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.